{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:41:05Z","timestamp":1793335265089,"version":"4.5.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neurogenic Bladder (NB) patients are highly susceptible to recurrent urinary tract infections (UTIs), often requiring repeated hospitalizations and prolonged antibiotic use. Current preventive strategies, including long-term antibiotics, frequently fail due to resistance and limited efficacy. Autovaccination, a form of personalized immunoprophylaxis using inactivated patient-specific bacterial strains, has shown potential in reducing UTI recurrence but has not been well studied in NB populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, single-center study was conducted at the Hospital Universitari i Polit\u00e9cnic La Fe Val\u00e8ncia, Spain. Eligible participants were individuals of any gender, aged between 18 and 65 years, with a confirmed diagnosis of NB. They were required to have experienced recurrent UTIs within the past twelve months, despite having undergone a six-month regimen of prophylactic antibiotics without success. Participants received a sublingual bacterial autovaccine (Uromune\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) prepared from uropathogens isolated from their own urine cultures. Primary outcomes included changes in hospitalization and emergency admission rates, while secondary outcomes assessed UTI-free time and patient-reported outcomes using validated instruments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 71 adult NB patients with recurrent UTIs. Autovaccination significantly reduced hospitalizations (from 1.76 \u00b1 3.47 to 0.78 \u00b1 1.38, p &amp;lt; 0.001) and emergency admissions (from 8.62 \u00b1 6.35 to 3.93 \u00b1 4.48, p &amp;lt; 0.001). At 3, 6, 9, and 12 months post-treatment, UTI-free rates were 69.1%, 42.6%, 29.4%, and 20.6%, respectively. Most patients reported high satisfaction and perceived clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Autovaccination appears to be a promising strategy for reducing the burden of recurrent UTIs in NB patients, with high patient satisfaction and fewer hospital visits. These findings support the need for larger, multicenter trials to confirm efficacy and define optimal treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1626422","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:11Z","timestamp":1754026391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Autovaccine immunoprophylaxis in patients with neurogenic bladder experiencing recurrent urinary tract infections"],"prefix":"10.3389","volume":"16","author":[{"given":"Miguel \u00c1ngel","family":"Bonillo-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo Guzm\u00e1n","family":"Ordaz-Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ortiz-Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Oriol","family":"Colet-Guitert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mor\u00e1n-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mart\u00ednez-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arlandis-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713876","article-title":"Neurogenic bladder: epidemiology, diagnosis, and management","volume":"40","author":"Panicker","year":"2020","journal-title":"Semin Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3978\/j.issn.2223-4683.2016.01.06","article-title":"Urinary tract infection in the neurogenic bladder","volume":"5","author":"Vigil","year":"2016","journal-title":"Transl Androl Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2015.05.006","article-title":"Urinary tract infection and neurogenic bladder","volume":"42","author":"McKibben","year":"2015","journal-title":"Urol Clin North Am"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2019.02.006","article-title":"Urinary tract infections in patients with neurogenic bladder","volume":"49","author":"Dinh","year":"2019","journal-title":"M\u00e9decine Maladies Infectieuses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S113610","article-title":"Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions","volume":"9","author":"Pannek","year":"2017","journal-title":"Res Rep Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.euf.2019.11.002","article-title":"Role of vaccines for recurrent urinary tract infections: A systematic review","volume":"6","author":"Prattley","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.04.002","article-title":"Bacterial vaccines for the management of recurrent urinary tract infections: A systematic review and meta-analysis","volume":"10","author":"Mak","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6690","article-title":"Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future","volume":"14","author":"Nickel","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094943","article-title":"Strategies to Tackle Antimicrobial Resistance: The Example of Escherichia coli and Pseudomonas aeruginosa","volume":"22","author":"Antonelli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12030359","article-title":"An effective sublingual vaccine, MV140, safely reduces risk of recurrent urinary tract infection in women","volume":"12","author":"Nickel","year":"2023","journal-title":"Pathogens"},{"key":"B11","article-title":"Immunoactive prophylaxis protocol of uncomplicated recurrent urinary tract infections in a cohort of 1104 women treated with uromune(\u00ae) vaccine","volume":"14","author":"Ram\u00edrez Sevilla","year":"2024","journal-title":"Life (Basel)"},{"key":"B12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12879-019-4541-y","article-title":"Active immunoprophyilaxis with uromune\u00ae decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects","volume":"19","author":"Ram\u00edrez Sevilla","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"EVIDoa2100018","DOI":"10.1056\/EVIDoa2100018","article-title":"Sublingual MV140 for prevention of recurrent urinary tract infections","volume":"1","author":"Lorenzo-G\u00f3mez","year":"2022","journal-title":"NEJM Evid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675735","article-title":"Sublingual bacterial vaccination reduces recurrent infections in patients with autoimmune diseases under immunosuppressant treatment","volume":"12","author":"S\u00e1nchez-Ram\u00f3n","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14067","article-title":"First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune(\u00ae)","volume":"121","author":"Yang","year":"2018","journal-title":"BJU Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-012-1853-5","article-title":"Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics","volume":"24","author":"Lorenzo-G\u00f3mez","year":"2013","journal-title":"Int Urogynecol J"},{"key":"B17","first-page":"50","article-title":"Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections","volume":"5","author":"Lorenzo-G\u00f3mez","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.093","article-title":"Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly","volume":"39","author":"Lorenzo-G\u00f3mez","year":"2021","journal-title":"Vaccine"},{"key":"B19","first-page":"25","article-title":"MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study","volume":"18","author":"Nickel","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000505162","article-title":"Analysis of the efficacy of a sublingual bacterial vaccine in the prophylaxis of recurrent urinary tract infection","volume":"104","author":"Carri\u00f3n-L\u00f3pez","year":"2020","journal-title":"Urol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12879-025-10524-2","article-title":"Evaluating the use of Uromune(\u00ae) autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain","volume":"25","author":"Iftimie","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq4120","article-title":"A sublingual nanofiber vaccine to prevent urinary tract infections","volume":"8","author":"Kelly","year":"2022","journal-title":"Sci Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000521772","article-title":"Cost-effectiveness of a sublingual bacterial vaccine for the prophylaxis of recurrent urinary tract infections","volume":"106","author":"Carri\u00f3n-L\u00f3pez","year":"2022","journal-title":"Urol Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5489\/cuaj.8716","article-title":"MV140 sublingual vaccine proves promising in fighting recurrent urinary tract infections in women","volume":"18","author":"Hickling","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.acuro.2022.05.007","article-title":"Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections","volume":"47","author":"Ram\u00edrez-Sevilla","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euros.2024.03.010","article-title":"Reducing recurrent urinary tract infections in women with MV140 impacts personal burden of disease: secondary analyses of a randomized placebo-controlled efficacy study","volume":"63","author":"Curtis Nickel","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121426","article-title":"Immunoprophylaxis with MV140 is effective in the reduction of urinary tract infections-A prospective real-life study","volume":"12","author":"Lopes","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/039463200601900311","article-title":"In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes","volume":"19","author":"Lanzilli","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.56434\/j.arch.esp.urol.20227509.110","article-title":"A focus on long-term follow-up of immunoprophylaxis to recurrent urinary tract infections: 10 years of experience with MV140 vaccine in a cohort of 1003 patients support high efficacy and safety","volume":"75","author":"Ram\u00edrez Sevilla","year":"2022","journal-title":"Arch Esp Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bju.16247","article-title":"Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double-blind randomized controlled trial protocol","author":"Kovacic","year":"2024","journal-title":"BJU Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1066383","article-title":"Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections","volume":"13","author":"Mart\u00edn-Cruz","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612269","article-title":"A combination of polybacterial MV140 and candida albicans V132 as a potential novel trained immunity-based vaccine for genitourinary tract infections","volume":"11","author":"Martin-Cruz","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215576648","article-title":"Urinary tract infections in women with stress urinary incontinence treated with transobturator suburethral tape and benefit gained from the sublingual polibacterial vaccine","volume":"7","author":"Lorenzo G\u00f3mez","year":"2015","journal-title":"Ther Adv Urol"},{"key":"B34","volume-title":"EAU guidelines on urological infections","author":"Bonkat","year":"2025"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/0269215520946065","article-title":"Immunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial","volume":"34","author":"Wade","year":"2020","journal-title":"Clin Rehabil"},{"key":"B36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0022-5347(17)40084-X","article-title":"Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial","volume":"143","author":"Hachen","year":"1990","journal-title":"J Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23859","article-title":"Effects of oral immunomodulation therapy on urinary tract infections in individuals with chronic spinal cord injury-A retrospective cohort study","volume":"38","author":"Krebs","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"B38","article-title":"Does bacterial vaccine become clinically significant in neurogenic bladder patients at clean intermittent catheterization","author":"Ordaz Jurado","year":"2014","journal-title":"Int Continence Soc"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.07.012","article-title":"Definitions of urinary tract infection used in interventional studies involving neurourological patients-A systematic review","volume":"8","author":"Sartori","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00069.x","article-title":"The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue\u2013the BSW","author":"Pleil","year":"2005","journal-title":"Value Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.medcli.2011.11.013","article-title":"Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder","volume":"140","author":"Errando-Smet","year":"2013","journal-title":"Med Clin (Barc)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000002204","article-title":"Retrospective cohort study of patient-reported urinary tract infection signs and symptoms among individuals with neurogenic bladder","volume":"102","author":"Wirth","year":"2023","journal-title":"Am J Phys Med Rehabil"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20126079","article-title":"Internal and external barriers to bladder management in persons with neurologic disease performing intermittent catheterization","volume":"20","author":"Herbert","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.46292\/sci21-00006","article-title":"Independence of urinary symptoms and urinary dipstick results in voiders with neurogenic bladder","volume":"28","author":"Groah","year":"2022","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"B46","volume-title":"Neurogenic bladder and neurogenic lower urinary tract dysfunction","author":"Leslie","year":"2020"},{"key":"B47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12879-022-07235-3","article-title":"The prevalence of antibiotic-resistant and multidrug-resistant bacteria in urine cultures from inpatients with spinal cord injuries and disorders: an 8-year, single-center study","volume":"22","author":"\u0160\u00e1mal","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B48","unstructured":"Vaccines and immunization"},{"key":"B49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/microorganisms13020393","article-title":"Evaluation and analysis of costs associated with prophylaxis of recurrent urinary tract infections (RUTIs) in women","volume":"13","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2025","journal-title":"Microorganisms"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:14Z","timestamp":1754026394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2025.1626422"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1626422","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1626422"}}